Free shipping on all orders over $ 500

Icrucumab

Cat. No. M24537

All AbMole products are for research use only, cannot be used for human consumption.

Icrucumab Structure
Synonym:

Anti-VEGFR1/FLT1 Reference Antibody IMC-18F1

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?
Quality Control & Documentation
Biological Activity

Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a humanized Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors.

Chemical Information
CAS Number 1024603-92-6
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
References

[1] Gang Yin, et al. J Chemother. Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials

[2] Linda T Vahdat, et al. Oncologist. Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer

[3] M Moore, et al. Ann Oncol. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy

[4] Daniel P Petrylak, et al. J Clin Oncol. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial

[5] Patricia M LoRusso, et al. Invest New Drugs. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study

Related VEGFR/PDGFR Products
Conbercept

Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc.
SU5208 

SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).
VEGFR-IN-1 

VEGFR-IN-1 is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively.
(Z)-Orantinib

(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively.
(Rac)-SAR131675 

(Rac)-SAR131675 is the racemate of SAR131675.
  Catalog
Abmole Inhibitor Catalog




Keywords: Icrucumab, Anti-VEGFR1/FLT1 Reference Antibody IMC-18F1 supplier, VEGFR/PDGFR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.


 
Get to Know Us
Customer Support
Resources
Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.